Drugs / Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains (QIV-SD)
Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains (QIV-SD)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04137887 Comparator | Nov 2019 → May 2020 | — | Sanofi Pasteur, a Sanofi Company | Terminated | Missed primary Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains (QIV-SD) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04137887 ↗ |
| Modality | Vaccine | “Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains (QIV-SD)” NCT04137887 ↗ |
| Route | Intramuscular | “Route of administration: Intramuscular” NCT04137887 ↗ |